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Abstract
Question
What evidence is available regarding the use of whole
brain radiation therapy (WBRT), stereotactic radiosurgery
(SRS), surgical resection or chemotherapy for the treat-
ment of recurrent/progressive brain metastases?
Target population
This recommendation applies to adults with recurrent/
progressive brain metastases who have previously been
treated with WBRT, surgical resection and/or radiosurgery.
Recurrent/progressive brain metastases are deﬁned as
metastases that recur/progress anywhere in the brain (ori-
ginal and/or non-original sites) after initial therapy.
Recommendation
Level3Sincethereisinsufﬁcientevidencetomakedeﬁnitive
treatment recommendations in patients with recurrent/
progressive brain metastases, treatment should be individu-
alized based on a patient’s functional status, extent of dis-
ease, volume/number of metastases, recurrence or
progression at original versus non-original site, previous
treatment and type of primary cancer, and enrollment in
clinical trials is encouraged. In this context, the follow-
ing can be recommended depending on a patient’s spe-
ciﬁc condition: no further treatment (supportive care), re-
irradiation (either WBRT and/or SRS), surgical excision or,
to a lesser extent, chemotherapy.
Question
If WBRT is used in the setting of recurrent/progressive
brain metastases, what impact does tumor histopathology
have on treatment outcomes?
No studies were identiﬁed that met the eligibility criteria
for this question.
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Rationale
Untreated brain metastases have a median survival of about
4 weeks with almost all patients dying from neurological
rather than systemic causes [1]. The majority of studies
which have compared different modalities for the treatment
of brain metastases have focused on the management of
newly diagnosed patients. The role of WBRT, surgical
excision, SRS and chemotherapy for patients with newly
diagnosed brain metastases are addressed by other guide-
line papers in this series (Gaspar et al., Kalkanis et al.,
Linskey et al., and Mehta et al.).
For those individuals who survive long enough to
experience recurrence/progression of previously treated
brain metastases, no consensus on treatment exists. The
overall objective of this guideline paper is to systematically
review the existing data relevant to the treatment of
patients who develop recurrent/progressive brain metasta-
ses after initial therapy and to provide recommendations
based on this evidence.
The questions speciﬁcally addressed by this guideline
paper are:
1. What evidence is available regarding the use of WBRT,
SRS, surgical resection or chemotherapy for the treat-
ment of recurrent/progressive brain metastases?
2. If WBRT is used in this setting, what impact does
tumor histopathology have on treatment outcomes?
Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, Cochrane Database of Abstracts of
Reviews of Effects. A broad search strategy using a com-
bination of subheadings and text words was employed. The
search strategy is documented in the methodology paper
for this guideline series by Robinson et al. [2] Reference
lists of included studies were also reviewed.
Eligibility criteria
(a) What evidence is available regarding the use of
WBRT, SRS, surgical resection or chemotherapy for
the treatment of recurrent and/or progressive brain
metastases?
• Published in English with a publication date of
1990 forward.
• Patients with recurrent and/or progressive brain
metastases.
• Fully-published primary studies (all study designs
for primary data collection included; e.g., RCT,
non-randomized trials, cohort studies, case–
control studies or case series).
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123• AnystudyevaluatingtheuseofWBRT,SRS,surgical
excision, or chemotherapy alone or in combination.
• Number of study participants with recurrent and/
or progressive brain metastases[5 per study arm
for comparative studies and [5 overall for non-
comparative studies.
• For studies evaluating interventions exclusively in
patients with recurrent and/or progressive brain
metastases, baseline characteristics of study par-
ticipants are provided by treatment group for
comparative designs and overall for non-compar-
ative studies. For studies with mixed populations
(i.e., includes participants with conditions other
than recurrent and/or progressive brain metasta-
ses), baseline characteristics are provided for the
sub-group of participants with recurrent and/or
progressive brain metastases, and stratiﬁed by
treatment group for comparative studies.
(b) If WBRT is used, what impact does tumor histopa-
thology have on treatment outcomes?
• Published in English with a publication date of
1990 forward.
• Patients with recurrent and/or progressive brain
metastases.
• Fully-published peer-reviewed primary studies
(all study designs for primary data collection
included; e.g., RCT, non-randomized trials, cohort
studies, case–control studies or case series).
• Any study evaluating the outcome(s) of WBRT by
tumor histopathology (or primary tumor type).
• Number of study participants with recurrent and/
or progressive brain metastases[5 per study arm
for comparative studies and [5 overall for non-
comparative studies.
• For studies evaluating the outcome(s) of WBRT by
histopathology (or primary tumor type) exclusively
in patients with recurrent and/or progressive brain
metastases, baseline characteristics are presented and
stratiﬁed by histologic/primary tumor group. For
studies with mixed populations (i.e., includes partic-
ipants with conditions other than recurrent and/or
progressivebrainmetastases),baselinecharacteristics
are presented and stratiﬁed by histologic/primary
tumor group for the sub-group of participants with
recurrent and/or progressive brain metastases.
Study selection and quality assessment
Two independent reviewers evaluated citations using a pri-
ori criteria for relevance and documented decisions in stan-
dardized forms. Cases of disagreement were resolved by a
third reviewer. The same methodology was used for full text
screening of potentially relevant papers. Studies which met
the eligibility criteria were data extracted by one reviewer
and the extracted information was checked by a second
reviewer.The PEDroscale [3,4]was used torate the quality
of randomized trials. The quality of comparative studies
using non-randomized designs was evaluated using eight
items selected and modiﬁed from existing scales.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper accompanying this
guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
What evidence is available regarding the use of WBRT,
SRS, surgical resection or chemotherapy for the treat-
ment of recurrent/progressive brain metastases?
In total, 30 studies met the eligibility criteria for this
question (Fig. 1). Of these studies, three evaluated the use
of WBRT [5–7], four addressed the role of surgical
resection [8–11], 13 reported on the use of radiosurgery
[12–24] and 10 evaluated chemotherapeutic agents [25–34]
for the treatment of recurrent/progressive brain metastases.
The details of each are outlined in Tables 1, 2, 3, 4.
No class I or II evidence was identiﬁed that speciﬁcally
addressed the question of which therapies (i.e., repeated
WBRT, SRS, surgery or chemotherapy) were beneﬁcial in
the setting of recurrent/progressive metastatic brain. In
fact, only one of the 30 included studies compared different
modalities for the treatment of recurrent/progressive brain
metastases [15]. The remaining 29 papers provide non-
comparative outcome data on the treatment of recurrent/
progressive brain metastases.
WBRT
Three case series addressed the question of whether
re-administration of WBRT was beneﬁcial for patients in
J Neurooncol (2010) 96:85–96 87
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progressed [5–7] (Table 1). These studies are retrospective
analyses of 52, 72 and 86 patients, respectively, and they
offer only very limited data as to whether patients died from
neurologic causes versus systemic disease progression. The
average re-irradiation dose for these patients was in the
range of 20–25 Gy over multiple fractions. The post-
re-irradiation median survival was 4 or 5 months in all of
the series.
In the largest of the case series (n = 86), 70% of
patients had either complete or partial resolution of neu-
rological symptoms following re-irradiation. In the two
other case series, the percentage of patients whose neuro-
logic function improved following re-irradiation was 42%
and 31%, respectively [5, 6].
One patient experienced symptoms of dementia attrib-
uted to radiation therapy in each of the two series reporting
information on longer term adverse effects [6, 7].
Title and Abstract Screening 
n=16,966 
Full Text Screening 
n=81 
Excluded at Title and 
Abstract 
n=16,885 
Eligible Studies 
n=30 
51 Excluded 
No patient data by recurrent subgroup................34 
No population of interest ……………..................5 
No treatment comparison of interest …………....4 
No patient data by treatment group………...........3 
n  ≤  5 for recurrent sub-group …………………...3 
No extractable data……………………….…...... 1 
Abstract only.........................................................1 
30 Included 
WBRT…………………………….3 
Surgery……………………………4 
SRS………………………………13 
Chemotherapy……………………10
Fig. 1 Flow of studies to ﬁnal
number of eligible studies of
retreatment of recurrent brain
metastases
Table 1 Re-irradiation with WBRT for recurrent/progressive brain metastases
First author
(Year)
Study design/
evidence class
Intervention
(# pts)
Population/previous
treatment
Median
survival
# Pts with
recurrence/
progression after
retreatment
a
Median time
to recurrence/
progression after
retreatment
Cooper [5]
(1990)
Case series WBRT (n = 52) Recurrent/progressive BM Median: NR NR NR
Evidence class III Mean survival:
22.4 weeks
Initial treatment: WBRT
Sadikov [6]
(2007)
Case series WBRT (n = 72) Recurrent/progressive BM 4.1 months NR NR
Evidence class III Initial treatment: WBRT
Wong [7]
(1997)
Case series WBRT (n = 86) Recurrent/progressive BM 4.0 months NR NR
Evidence class III Initial treatment: WBRT
BM Brain metastases, NR Not reported, Pts Patients, WBRT Whole-brain radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
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WBRT in the setting of recurrent/progressive brain metas-
tases for patients whose initial management did not include
WBRT.
Surgical resection
Four cases series addressed the use of surgical resection for
recurrent/progressive brain metastases [8–11], as outlined
in Table 2. Two of these retrospective studies reported
outcomes for patients who underwent surgical resection for
recurrent/progressive brain metastases who also had pre-
viously been treated with SRS ± WBRT [10, 11]. In the
study by Vecil et al. 61 patients with three or fewer
recurrent brain metastases underwent surgical resection for
at least one index brain metastasis [11]. Treatment of
non-index brain metastases varied. Major surgical com-
plications occurred in seven patients. From the date of
resection, median survival was 11.1 months and median
time to any recurrence in the brain was 5 months. Cause of
death was neurologic in 15% of patients and neurologic/
systemic combined in 34%. The second study, conducted
by Truong et al., included 32 patients who had previously
been treated with SRS and who had MRI and/or clinical
evidence of brain metastasis progression. To be considered
for surgical resection, patients needed to have a KPS C60
and stable or absent systemic disease. Median survival
from the time of resection was 8.9 months. Seven patients
experienced surgical complications. Cause of death was
neurologic in 48% of patients [10].
Two case series evaluated the outcome of re-operation
for recurrent brain metastases [8, 9]. Bindal et al. reported
on 48 patients who had surgical resection of a brain
metastasis as part of their initial treatment and then
underwent resection for recurrent disease. From the time of
re-operation, median survival was 11.5 months and the
median time to recurrence was 7.7 months. Of the 26
patients who developed a second recurrence, 17 underwent
another surgical resection. For the 25 patients in which
cause of death was known, it was neurologic in 48% and
combined neurologic/systemic in 12% [9]. As part of a
larger study, Arbit et al., provide retrospective data on 32
patients with non-small cell lung cancer (NSCLC) who
underwentre-operation forrecurrent brainmetastases. From
Table 2 Surgical resection for recurrent/progressive brain metastases
First
author
(Year)
Study
design/
evidence
class
Intervention
(# pts)
Population/
previous treatment
Median
survival
# Pts with
recurrence/
progression after
retreatment
a
Median time
to recurrence/
progression after
retreatment
Arbit [8]
(1995)
Case series Surgery
(n = 32)
Recurrent BM from
NSCLC
10 months NR NR
Evidence
class III
Initial treatment included
surgical resection
Bindal [9]
(1995)
Case series Surgery
(n = 48)
Recurrent BM 11.5 months At original site only:
18/48 (38%)
Overall in brain:
7.7 months Initial treatment: surgical
resection ± WBRT Evidence
class III
At distant brain site only:
3/48 (6%)
At original ? distant sites:
5/48 (10%)
Overall in brain: 26/48 (54%)
Truong [10]
(2006)
Case series Surgery
(n = 32)
Recurrent/progressive BM 8.9 months At original site: 9/32 (28%) At original site:
6.2 months Evidence
class III
BM had been previously
treated with SRS (either
as initial or salvage
treatment)
Vecil[11]
(2005)
Case series Surgery
(n = 61)
Recurrent/progressive B3
BM
11.1 months At original site only: 4/61 (7%) Overall in brain:
5 months
Evidence
class III
At distant brain site only:
19/61 (31%)
At distant sites in
brain: 8.4 months
Initial treatment: SRS
At original ? distant sites:
9/61 (15%)
At original site:
Median: could
not be estimated
BM Brain metastases, NR Not reported, NSCLC Non-small cell lung cancer, Pts Patients, SRS Stereotactic radiosurgery, WBRT Whole-brain
radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
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123the date of re-operation, median survival was 10 months.
Time to recurrence/progression was not reported [8].
SRS
Thirteen studies addressed the role of SRS for recurrent/
progressive brain metastases [12–24]. Nine studies evalu-
ated the use of SRS for recurrent/progressive disease in
patients whose initial management included WBRT
[12, 14–17, 19–22]. One of these studies was prospective
[16]. This single-arm phase I/II study enrolled 12 patients
whose life expectancy was C3 months and who had both
clinical and radiologic evidence of brain metastases pro-
gression following treatment with WBRT. All patients were
followed to recurrence at the SRS treated site or until death.
In total, 20 brain metastases in the 12 patients were treated
by radiosurgery. From the date of SRS treatment, median
survival was 6 months. Nine patients developed evidence of
progressive disease at SRS treated sites. Time to progression
was not reported. Of the other eight studies that addressed
the role of SRS for recurrent disease in patients whose
upfront treatment included WBRT, four speciﬁcally evalu-
ated SRS treatment for recurrent/progressive brain metas-
tases from particular primary tumor types–breast cancer
(2 case series [12, 14]), small cell lung cancer (SCLC)
(1 case series [22]) and lung cancer, predominantly NSCLC
(1 case series [17]). See Table 3 for details.
The only comparative study that met the eligibility cri-
teria for the systematic review evaluated single-dose SRS
versus split-dose (2 dose) SRS for recurrent/progressive
disease in 104 patients whose initial management included
WBRT [15]. In this retrospective cohort study with his-
torical controls, median survival was signiﬁcantly longer
for patients who received split-dose SRS compared to
single-dose SRS (30 vs. 16 weeks; p = 0.015). Time to
recurrence/progression was not reported.
Four case series evaluated the use of SRS for recurrent/
progressive brain metastases in patients whose previous
treatment included radiosurgery [13, 18, 23, 24], as outlined
in Table 3. Only two of these case series provide survival
data from the date of SRS for recurrent disease [13, 18]. In
the series by Kwon et al., of 43 patients who underwent
salvage SRS, median survival from the time of SRS for
recurrent/progressive disease was 32 weeks and the local
control rate at 6 months was 91% [18]. In the case series by
Chen et al., of 45 patients, median survival from the time of
SRS for recurrent brain metastases was 28 weeks [13]. The
1 year freedom from progression rate was 94%.
Chemotherapy
Ten studies evaluated the role of chemotherapy in patients
with recurrent/progressive metastatic brain disease [25–34].
Ofthese,ﬁveareprospectivesinglearmphaseIIstudies[25,
27, 29, 31, 32] and ﬁve are case series [26, 28, 30, 33, 34].
Refer to Table 4 for details. The agents used in these studies
varied from intracarotid administration of cisplatin, to tem-
ozolomide alone or with thalidomide, vinorelbine, fote-
mustine or cisplatin. Five of the studies investigated the role
of chemotherapy speciﬁcally for patients with recurrent/
progressive brain metastases from particular primary tumor
types—melanoma (3 studies) [26, 28, 31], NSCLC (1 study)
[29], and SCLC (1 study) [30].
Median survival in patients with recurrent/progressive
brainmetastases treatedwith chemotherapy ranged from3.5
to 6.6 months [25–34]. The median time to recurrence after
retreatment with chemotherapy in these studies ranged from
2to4 months.Thesestudiesindicatethatsomepatientswith
recurrent or progressive brain metastases will have an
objective radiographic response and/or improvement in
functional status after treatment with chemotherapy.
If WBRT is used in the setting of recurrent and/or
progressive brain metastases, what impact does tumor
histopathology have on treatment outcomes?
No studies were identiﬁed that met the eligibility criteria
for this question.
Discussion and conclusions
No studies that provide class I or II evidence were identi-
ﬁed which met the eligibility criteria and speciﬁcally
addressed the question of which adjuvant therapies (i.e.,
WBRT, SRS, surgical resection or chemotherapy) are
beneﬁcial in the setting of recurrent/progressive metastatic
brain tumors. Furthermore, all but one of the included
studies that provide class III evidence on this topic are non-
comparative. While multiple randomized clinical trials
have examined the beneﬁts for up-front combined therapies
(e.g., WBRT plus SRS, WBRT plus surgery), none have
been performed speciﬁcally to address the question of the
beneﬁts of further SRS, surgery or chemotherapy in cases
of recurrent/progressive brain metastases. Therefore, no
level 1 or level 2 recommendations can be made.
Given that none of the included studies compared the
different modalities (WBRT, SRS, surgical resection or
chemotherapy) for the treatment of recurrent/progressive
brain metastases, the relative merits of one approach versus
another are yet to be determined. Furthermore, retrospective
studies of patients with recurrent/progressive brain metas-
tases who have previously undergone WBRT, and then
received subsequent re-irradiation, show conﬂicting results
with regard to neurologic improvement and quality of life.
It is recommended that treatment of recurrent/progres-
sive brain metastases be individualized based on functional
status, extent of disease, volume/number of metastases,
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123recurrence or progression at original versus non-original
site, previous treatment and type of primary cancer. In this
context, re-irradiation (either WBRT and/or SRS), surgical
excision or, to a lesser extent, chemotherapy, can be rec-
ommended depending on a patient’s speciﬁc condition and
based on the judgment of the patient’s treating physician.
As no studies were identiﬁed that met the eligibility cri-
teria for the question addressing whether tumor histopa-
thology impacts treatment outcomes when WBRT is used in
the setting of recurrent/progressive brain metastases, no
evidence-basedrecommendationscanbemadeonthistopic.
Key issues for further investigation
This systematic review of the evidence highlights the
critical need for comparative studies that directly evaluate
the outcome of different treatment modalities for patients
with recurrent/progressive metastatic brain disease, while
simultaneously addressing the role of tumor histopathology
in treatment outcomes. In addition, understanding potential
differences in the mode of death (neurologic versus sys-
temic progression), will help answer the important question
of whether treating recurrent/progressive lesions delays
neurologic progression long enough to allow more
aggressive therapy for the primary systemic disease.
Moreover, speciﬁc patient characteristics offer impor-
tant clinical variables in evaluating treatment for recurrent/
progressive metastases, such as if the recurrence/progres-
sion occurs at the site of the primary focal treatment
(surgery or SRS) and if it is clinically symptomatic or
discovered because of routine surveillance neuroimaging.
Indeed, as the treatment of recurrent/progressive brain
metastases is undertaken primarily with palliative intent, it
is important to stress which symptoms these treatments are
poised to address and how overall patient quality of life is
going to be affected by any re-treatment modality.
No ongoing or recently closed randomized clinical trials
addressing the re-treatment of patients with recurrent/
progressive brain metastases were found that met the eli-
gibility criteria.
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